Compare Global X Lithium & Battery Tech ETF (LIT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs Repligen Corporation Common Stock — how do they compare? Global X Lithium & Battery Tech ETF trades at $65 (market cap $1.45B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 7.8× Global X Lithium & Battery Tech ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 57 Days and Repligen Corporation Common Stock for 0 Days on average.
| LIT | RGEN | |
|---|---|---|
Market Cap | $1.45B | $11.31B |
Volume | 204,733 | 1,216,919 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $194.57 |
52-Week Low | $56.39 | $102.87 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT (Global X Lithium & Battery Tech ETF) trades at $67.65, down 1.05% with bearish technical signals from moving averages and oscillators. The ETF faces headwinds from volatile lithium prices and oversupply concerns, though long-term prospects remain supported by EV adoption trends. Recent news highlights significant short interest reduction and China's ambitious 30% EV fleet target by 2030.
Outlook is cautious near-term due to technical weakness and commodity volatility, but structural EV growth offers recovery potential. Risks include lithium price swings and geopolitical trade tensions, while institutional sentiment shows mixed signals with recent short covering.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
